国产固定剂量复合剂治疗肺结核的临床近期效果观察  

Controlled clinical study on efficacy of national fixed-dose compounds in antituberculosis chemotherapy

作　　者：初乃惠[1] 高孟秋[1] 马丽萍[1] 刘菲[1] 吴晓光[1] 王庆枫[1] 聂理会[1] 朱莉贞[1] 

机构地区：[1]北京市结核病胸部肿瘤研究所,北京101149

出　　处：《中国防痨杂志》2004年第6期341-343,共3页Chinese Journal of Antituberculosis

摘　　要：目的　评价国产固定剂量复合剂异烟肼利福平吡嗪酰胺 /异烟肼利福平 (2HRZ/ 4HR)的抗结核疗效及不良反应。方法　将 81例初治菌阳肺结核患者 ,随机分为治疗组 (2HRZ/ 4HR)和对照组(2HRZ/ 4HR) ,观察近期痰菌阴转率、X线病灶改变及不良反应。结果　治疗组和对照组 2月痰菌阴转率分别达 82 .5 %和 6 5 .7% ;满疗程痰菌阴转率各为 10 0 .0 %和 88.6 % ;胸部X线明显改善 ,治疗组和对照组病灶吸收分别占 92 .7%和 94 .3% ,两组空洞闭合率分别为 6 3.2 %和 6 2 .5 % ;治疗组和对照组各有 2例和 4例肝功异常。结论　国产固定复合剂是一种安全、高效、易被患者接受、具有推广应用前景的抗结核药物。Objective To evaluate the treatment outcome and si de-effects of national fixed-dose compounds (2HRZ/4HR).Methods 81 new bacteriological positive pulmonary tuberculosis patients were divided r andomly into treatment group (42 cases) and control (39 cases) group.Results The sputum negative conversion rates at the 2nd month i n the treatment and the control group were 82.5% and 65.7% respectively.And the rates at the end of the chemotherapy were 100.0% and 88.6% respectively.Chest ra diography showed remarkable improvement.The resolution of pulmonary lesions in t he treatment group and the control group accounted for 92.7% and 94.3% respectiv ely.The cavity closure rates were 63.2% in the treatment group and 62.5% in the control group.Two patients defaulted because of hepatic dysfunction in the t re atment group and 4 patients in the control’s.Conclusion Nation al fixed-dose compounds rifater/rifinah show excellent therapeutic efficacy,saf ety and compliance in antituberculous chemotherapy,which could be recommended fo r wider use in tuberculosis control in China.

关 键 词：对照组 治疗组 痰菌阴转率 观察 2HRZ/4HR 近期效果 病灶 结论 目的 方法 

分 类 号：R521[医药卫生—内科学] R554.6[医药卫生—临床医学]